The EBDC 2016 will examine topics such as trends in Immuno-oncology, cures for neurologic diseases as well as challenges and advantages in R&D of orphan medicinal products. We will also look at the financial landscape in Europe.
We will again offer this partnering website and platform, allowing you to meet privately with international decision makers from the biotech and pharmaceutical sectors, as well as other life sciences industry suppliers.
The conference programme will include company presentation of innovative biotech firms presenting their research, products and technologies to the other conference participants and investors.
The EBDC is an annual event that brings leading decision makers from international pharmaceutical companies and European biotech firms together with representatives of private equity and venture capital companies (see list of attending companies). The EBDC provides a forum for making contacts and discussing topics and trends of relevance to the market. The conference is attended by CEOs, managing directors and senior business development managers.
Representatives of the following companies have already confirmed their attendance:
Abviris, AC Immune, Aeterna Zentaris, AFFiRiS, AiCuris, Alexion, apceth, Apogenix, BAND, Bayer, BCNP Consultants, Beacon Cure, BEROCEUTICA, BioMedPartners, Bio-techne, Bone Therapeutics, CARBOGEN AMCIS, Cell Therapy, Constares, cpo - cellular phenomics & oncology Berlin-Buch, Creathor Venture Management, Cyprumed, Cytolon, emovis home care visits, FGK Clinical Research, Heidelberg Pharma, Hessen Trade and Invest, Janssen Cilag, Lipotype, Max-Planck-Innovation, Merck, Miltenyi Biotech, MSD, Pfizer, Phenex Pharmaceuticals, Probiodrug, PROGEN Biotechnologie, Protagen Protein Services, R-Biopharm, Rigontec, Sanofi, Science4Life, Sinfonie Life-Science-Management, SOBI, Sonovum, SPINDIAG, TauRX, Technologiepark Heidelberg, Vertex Pharma, xl-Protein, Zedira